GO:0045752 positive regulation of Toll signaling pathway: Activation Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045752 describes any process that activates or increases the frequency, rate or extent of the Toll signaling pathway, a conserved innate immune cascade.
• Positive regulation of Toll signaling is essential for host defense against pathogens and for shaping inflammatory responses.
• Dysregulated Toll signaling contributes to sepsis, metabolic dysfunction-associated steatohepatitis, vascular calcification, and other inflammatory diseases [1,2,4,5,6,7].
• Key positive regulators include TLR4, TLR9, MyD88, NF-κB, and MAPK components, while phosphatases provide negative feedback [3,8].
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of positive regulators in Toll signaling [3,8].
• Understanding GO:0045752 informs therapeutic strategies targeting innate immune activation in inflammatory and metabolic disorders [1,3,8].
Description
The Toll signaling pathway is an evolutionarily conserved innate immune mechanism that detects microbial components and endogenous danger signals, initiating rapid inflammatory and antimicrobial responses. Positive regulation of this pathway, formalized as GO:0045752, encompasses any process that activates or increases the frequency, rate or extent of Toll signaling, thereby amplifying host defense but also potentially driving pathology when unchecked. This GO term is critical for researchers because Toll signaling intersects with diverse disease processes, from infection and sepsis to metabolic disorders and vascular disease [1,3,6]. Experimental evidence shows that modulation of Toll signaling components can alter disease outcomes in models of nonalcoholic steatohepatitis, intestinal barrier dysfunction, and vascular calcification [1,2,4,5,6,7]. Understanding the positive regulators of Toll signaling provides a framework for therapeutic intervention and for interpreting genomic or pharmacological data in inflammation research [3,8].
positive regulation of Toll signaling pathway At A Glance
| GO ID | GO:0045752 |
|---|---|
| GO term | positive regulation of Toll signaling pathway |
| Ontology | biological_process |
| Synonym | activation of Toll signaling pathway; positive regulation of Tl signaling pathway; positive regulation of Tl signalling pathway; stimulation of Toll signaling pathway; up regulation of Toll signaling pathway; up-regulation of Toll signaling pathway; upregulation of Toll signaling pathway |
| Major function | Amplification of Toll receptor signaling to promote innate immune and inflammatory responses |
| Related pathways | TLR4/NF-κB/MAPK, TLR9-mediated endoplasmic reticulum stress, YAP/TAZ signaling [4,5,6] |
| Key positive regulators | TLR4, TLR9, MyD88, NF-κB, MAPK components [3,4,6] |
| Negative regulators | Protein phosphatases such as SHP-1, MKP-1, and others that dampen TLR signaling |
| Disease relevance | Sepsis, nonalcoholic steatohepatitis, metabolic dysfunction-associated steatohepatitis, vascular calcification, inflammatory bowel disease [1,2,4,5,6,7] |
What Is GO:0045752?
GO:0045752, positive regulation of Toll signaling pathway, refers to any biological process that activates or increases the frequency, rate or extent of the Toll signaling pathway, also known as Tl signaling. This includes molecular events such as ligand binding, receptor oligomerization, adaptor recruitment, kinase activation, and downstream transcription factor activation that collectively enhance signal transduction [3,8]. The term is a child of positive regulation of signal transduction and is specific to the Toll pathway, distinguishing it from positive regulation of other immune signaling cascades.
Why Is positive regulation of Toll signaling pathway Important in Cell Biology?
Positive regulation of Toll signaling is a central node in innate immunity, determining the magnitude and duration of inflammatory responses to infection and tissue damage. Its dysregulation is implicated in a wide range of human diseases, including sepsis, metabolic liver disease, and vascular calcification, making it a high-value target for both mechanistic studies and therapeutic development [1,2,4,5,6,7]. Researchers studying this process can identify novel positive regulators, understand feedback control by phosphatases, and evaluate how genetic or pharmacological interventions shift disease trajectories [3,8].
• Controls the intensity of innate immune responses to bacterial and viral pathogens.
• Amplifies NF-κB and MAPK signaling, driving proinflammatory cytokine production [3,4].
• Contributes to sepsis pathogenesis and intestinal barrier dysfunction.
• Promotes vascular calcification via lipopolysaccharide-induced NF-κB activation.
• Is implicated in nonalcoholic steatohepatitis and metabolic dysfunction-associated steatohepatitis [2,5,7].
• Provides targets for anti-inflammatory drug discovery, such as matrine and polydatin [2,4].
• Negative regulation by phosphatases prevents excessive inflammation and autoimmunity.
• Serves as a model for studying conserved signal transduction across species.
• Enables CRISPR-based functional genomics of immune signaling [3,8].
• Links innate immunity to metabolic and cardiovascular pathologies [1,5,7].
What Happens During positive regulation of Toll signaling pathway?
Ligand recognition and receptor activation
In simple terms: The pathway starts when microbial molecules or danger signals bind to Toll-like receptors, switching them on.
Positive regulation of Toll signaling begins with ligand binding to Toll-like receptors (TLRs) such as TLR4 by lipopolysaccharide (LPS) or TLR9 by CpG DNA [3,4,6]. This binding induces receptor dimerization and conformational changes that recruit adaptor proteins, thereby increasing the rate of downstream signaling. In models of vascular calcification, Prevotella copri-derived LPS activates NF-κB signaling through TLR4, illustrating how microbial ligands positively regulate the pathway.
Adaptor recruitment and kinase cascade activation
In simple terms: Once the receptor is active, it recruits helper proteins that pass the signal along like a relay race.
Activated TLRs recruit adaptors such as MyD88, which then assemble with IL-1 receptor-associated kinases (IRAKs) and TNF receptor-associated factor 6 (TRAF6) to propagate the signal. This assembly increases the frequency and extent of downstream phosphorylation events, including activation of TAK1 and IKK complexes. Positive regulation at this stage is often mediated by ubiquitination and scaffolding proteins that stabilize the signaling complex.
NF-κB and MAPK pathway amplification
In simple terms: The signal reaches transcription factors that turn on inflammatory genes, and positive regulators make this response stronger.
The kinase cascade culminates in activation of NF-κB and MAPK pathways, which translocate to the nucleus and induce proinflammatory cytokines and chemokines [3,4]. Positive regulation of Toll signaling enhances the magnitude of NF-κB nuclear translocation and MAPK phosphorylation, as seen with matrine modulating the TLR4/NF-κB/MAPK axis in LPS-stimulated macrophages. Similarly, Zhuyu pill regulates macrophage polarization through TLR4 signaling, demonstrating pharmacological control of this positive regulation.
Feedback and negative regulation by phosphatases
In simple terms: Brakes exist to stop the signal from going out of control, and these brakes are part of the regulatory balance.
Positive regulation is balanced by negative regulators, including protein phosphatases such as SHP-1 and MKP-1, which dephosphorylate key signaling intermediates and terminate the response. The interplay between positive and negative regulation determines the duration and intensity of Toll signaling, and disruption of this balance can lead to chronic inflammation [3,8]. Understanding these feedback mechanisms is essential for interpreting experiments that manipulate positive regulators.
Key Genes Involved in GO:0045752 positive regulation of Toll signaling pathway
The following genes and proteins are central to positive regulation of Toll signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TLR4 | Recognizes LPS and initiates MyD88-dependent signaling [3,4] | Target for anti-inflammatory drugs in sepsis and metabolic disease [4,7] |
| TLR9 | Detects CpG DNA and activates NF-κB [3,6] | Implicated in sepsis-induced intestinal barrier dysfunction |
| MYD88 | Central adaptor for most TLRs | Knockout models reveal essential role in Toll signaling |
| NFKB1 | Transcription factor driving proinflammatory gene expression [3,4] | Readout for pathway activation in macrophages |
| MAPK1 | Kinase in MAPK cascade downstream of TLRs [3,4] | Phosphorylation serves as activation marker |
| TRAF6 | E3 ubiquitin ligase that activates TAK1 | Positive regulator amplified in inflammatory models |
| IRAK4 | Kinase that initiates IRAK phosphorylation | Target for small molecule inhibitors |
| TAK1 | MAP3K that activates IKK and MAPK | Key node for positive regulation |
| IKBKB | IKKβ subunit that phosphorylates IκB | Essential for NF-κB activation |
| PTPN6 | Phosphatase SHP-1 that negatively regulates TLR signaling | Loss-of-function increases Toll signaling |
| DUSP1 | Phosphatase MKP-1 that dephosphorylates MAPK | Negative feedback regulator |
| YAP1 | Transcriptional co-activator linked to YAP/TAZ signaling | Modulates metabolic dysfunction-associated steatohepatitis |
| PPARGC1A | May influence metabolic inflammation | Potential crosstalk with Toll signaling |
| IL6 | Proinflammatory cytokine induced by Toll signaling | Biomarker of pathway activation |
| TNF | Cytokine upregulated by NF-κB | Readout for positive regulation |
| CXCL8 | Chemokine induced by TLR activation | Marker of inflammatory response |
| CD14 | Co-receptor for LPS recognition | Enhances TLR4 sensitivity |
How Is positive regulation of Toll signaling pathway Regulated?
Positive regulation of Toll signaling is controlled by a balance of activating and inhibitory mechanisms. Protein phosphatases such as SHP-1 and MKP-1 provide negative feedback by dephosphorylating key intermediates, thereby preventing excessive inflammation. Conversely, ubiquitination and scaffolding proteins stabilize signaling complexes to enhance pathway output. Pharmacological agents like polydatin, matrine, and Zhuyu pill have been shown to modulate Toll signaling in models of steatohepatitis and inflammation, indicating that this pathway is amenable to external regulation [2,4,7]. Additionally, crosstalk with YAP/TAZ signaling has been implicated in metabolic dysfunction-associated steatohepatitis, suggesting integration with other regulatory networks.
positive regulation of Toll signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TLR4 | Metabolic dysfunction-associated steatohepatitis, sepsis [4,7] | LPS-stimulated macrophages, diet-induced NASH mice [2,4] |
| TLR9 | Sepsis-induced intestinal barrier dysfunction | Cecal ligation and puncture sepsis model |
| NFKB1 | Vascular calcification, inflammation | Vascular smooth muscle cell calcification assays |
| PTPN6 | Autoinflammation due to loss of negative regulation | Knockout mice or CRISPR KO cells |
| YAP1 | Metabolic dysfunction-associated steatohepatitis | High-fat diet mouse models |
Inflammatory and infectious diseases
Positive regulation of Toll signaling is critical for host defense, but excessive activation contributes to sepsis and intestinal barrier dysfunction. Neutrophil extracellular traps impair intestinal barrier function in sepsis by regulating TLR9-mediated endoplasmic reticulum stress, highlighting a pathogenic role for TLR9 signaling. Similarly, Prevotella copri promotes vascular calcification via LPS through NF-κB activation, linking microbial Toll signaling to cardiovascular pathology.
Metabolic liver diseases
Toll signaling is implicated in nonalcoholic steatohepatitis and metabolic dysfunction-associated steatohepatitis. Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice, partly through modulation of inflammatory pathways. Zhuyu pill attenuates metabolic-associated fatty liver disease by regulating macrophage polarization through TLR4 signaling, demonstrating that positive regulation of Toll signaling can be targeted pharmacologically. Injinoryeong-San also attenuates metabolic dysfunction-associated steatohepatitis via YAP/TAZ signaling, which may intersect with Toll pathways.
Vascular and metabolic disorders
Vascular calcification is promoted by Prevotella copri-derived LPS through NF-κB activation, a downstream consequence of Toll signaling. This suggests that positive regulation of Toll signaling contributes to ectopic calcification and cardiovascular risk. Targeting this pathway may offer therapeutic benefit in vascular disease.
From positive regulation of Toll signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X positively regulate Toll signaling? | CRISPR knockout in macrophage cell lines (e.g., RAW 264.7) followed by LPS stimulation |
| Does a point mutation in TLR4 alter ligand sensitivity? | CRISPR point mutation knock-in in primary macrophages or cell lines |
| Does overexpression of a candidate gene amplify NF-κB activation? | Lentiviral overexpression in HEK293T or reporter cell lines |
| Does a tagged knock-in reveal spatiotemporal dynamics? | CRISPR knock-in of fluorescent tag (e.g., GFP) into endogenous locus |
| Which phosphatases negatively regulate Toll signaling? | CRISPR knockout library screening for hyperactivation |
| Can pharmacological agents modulate Toll signaling in vivo? | Mouse models of NASH or sepsis treated with compounds [2,4,7] |
How to Study the positive regulation of Toll signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptional changes | Identify genes induced by Toll activation |
| Phospho-Western blot | Activation of NF-κB and MAPK | Quantify positive regulation after LPS [3,4] |
| NF-κB luciferase reporter | Transcriptional activity of NF-κB | High-throughput screening |
| ELISA | Cytokine secretion (TNF, IL-6) | Functional readout of Toll signaling |
| Immunofluorescence | NF-κB nuclear translocation | Single-cell analysis |
| CRISPR knockout screening | Identify positive regulators | Functional genomics |
| Proteomics | Protein abundance and modifications | Discover signaling components |
Transcriptomic and proteomic profiling
RNA-seq and proteomics can identify global changes in gene expression and protein abundance following manipulation of positive regulators of Toll signaling. For example, LPS-stimulated macrophages treated with matrine show altered expression of TLR4/NF-κB/MAPK pathway components. Proteomic analysis of phosphatase knockouts can reveal hyperphosphorylated substrates.
Phospho-specific signaling assays
Western blotting for phosphorylated NF-κB p65, IκBα, p38, JNK, and ERK is commonly used to measure activation of Toll signaling [3,4]. These assays provide quantitative readouts of positive regulation and are amenable to time-course experiments.
Reporter gene and cytokine assays
NF-κB luciferase reporters and ELISA for cytokines such as TNF, IL-6, and CXCL8 are standard methods to assess Toll signaling output [3,4]. These functional readouts are useful for high-throughput screening of positive regulators.
Imaging and spatial analysis
Fluorescence microscopy of NF-κB nuclear translocation and co-localization of TLRs with adaptors can visualize positive regulation in single cells. Knock-in of fluorescent tags enables real-time tracking of signaling complexes.
How CRISPR Can Be Used to Study GO:0045752 positive regulation of Toll signaling pathway
Knockout
CRISPR knockout of candidate positive regulators (e.g., TLR4, MYD88, TRAF6) in macrophage cell lines or primary cells can determine whether they are required for Toll signaling activation. Loss of these genes typically reduces NF-κB and MAPK activation upon LPS stimulation [3,4]. Knockout of phosphatases such as PTPN6 can enhance signaling, confirming negative regulation.
Point Mutation
CRISPR point mutation can introduce specific amino acid substitutions to test the function of phosphorylation sites or ubiquitination sites in positive regulators. For example, mutating key residues in IRAK4 or TAK1 can reveal their role in signal amplification. This approach is valuable for dissecting structure-function relationships.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins into endogenous loci allows for tracking of positive regulators in real time. Tagged knock-in of MyD88 or TRAF6 can reveal recruitment dynamics to TLRs. This method preserves endogenous regulation and avoids overexpression artifacts.
Overexpression
Overexpression of candidate positive regulators via lentiviral transduction can test sufficiency for pathway activation. For instance, overexpressing a kinase may enhance NF-κB activation even at low ligand concentrations. This approach is useful for gain-of-function studies and for validating screening hits.
How EDITGENE Supports positive regulation of Toll signaling pathway Research
Researchers studying positive regulation of Toll signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway activation or whether it merely correlates with inflammatory responses. CRISPR-based models provide the gold standard for establishing causality, enabling precise genetic perturbations in relevant cell types such as macrophages and epithelial cells [3,8].
Contact EDITGENE today to design your custom CRISPR model for positive regulation of Toll signaling pathway research.
Frequently Asked Questions About positive regulation of Toll signaling pathway
What is GO:0045752?
GO:0045752 is the Gene Ontology term for positive regulation of Toll signaling pathway, describing any process that activates or increases the frequency, rate or extent of Toll signaling.
What genes are involved in positive regulation of Toll signaling pathway?
Key genes include TLR4, TLR9, MYD88, TRAF6, IRAK4, TAK1, IKBKB, NFKB1, and MAPK1, as well as negative regulators like PTPN6 and DUSP1 [3,4,6,8].
How is Toll signaling positively regulated?
Positive regulation occurs through ligand binding, receptor dimerization, adaptor recruitment, kinase cascade activation, and NF-κB/MAPK amplification, balanced by phosphatase-mediated negative feedback [3,8].
What diseases are associated with dysregulated Toll signaling?
Dysregulated Toll signaling is associated with sepsis, nonalcoholic steatohepatitis, metabolic dysfunction-associated steatohepatitis, vascular calcification, and inflammatory bowel disease [1,2,4,5,6,7].
What experimental models are used to study positive regulation of Toll signaling?
Common models include LPS-stimulated macrophages, CRISPR knockout cell lines, reporter gene assays, and mouse models of sepsis or steatohepatitis [3,4,6,7].
How can CRISPR be used to study positive regulators of Toll signaling?
CRISPR knockout, point mutation, knock-in, and overexpression can establish causality for candidate genes in Toll signaling activation [3,8].
What are the negative regulators of Toll signaling?
Protein phosphatases such as SHP-1 (PTPN6) and MKP-1 (DUSP1) dephosphorylate signaling intermediates to dampen Toll signaling.
Which cytokines are induced by Toll signaling?
TNF, IL-6, and CXCL8 are commonly induced downstream of Toll signaling activation [3,4].
How is Toll signaling linked to metabolic liver disease?
Toll signaling promotes inflammation in nonalcoholic steatohepatitis and metabolic dysfunction-associated steatohepatitis, and compounds like polydatin and Zhuyu pill modulate this pathway [2,7].
What is the role of TLR4 in vascular calcification?
TLR4 mediates LPS-induced NF-κB activation, which promotes vascular calcification in models treated with Prevotella copri-derived LPS.
Conclusion
GO:0045752, positive regulation of Toll signaling pathway, is a fundamental biological process that governs the intensity of innate immune responses. Its dysregulation contributes to a spectrum of inflammatory and metabolic diseases, making it a critical area of research. Advances in CRISPR-based models and functional genomics are accelerating the discovery of positive regulators and their therapeutic potential [3,8]. Continued investigation of this pathway will likely yield new strategies for treating inflammatory diseases.
References
- 1. Hao QY et al.. 2024. Prevotella copri promotes vascular calcification via lipopolysaccharide through activation of NF-κB signaling pathway.. Gut Microbes 16(1):2351532 PMID: 38727248
- 2. Li R et al.. 2018. Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice.. Int J Biol Sci 14(11):1411-1425 PMID: 30262993
- 3. O'Neill LA. 2008. When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction.. Immunity 29(1):12-20 PMID: 18631453
- 4. Mao N et al.. 2024. Preventive effects of matrine on LPS-induced inflammation in RAW 264.7 cells and intestinal damage in mice through the TLR4/NF-κB/MAPK pathway.. Int Immunopharmacol 143(Pt 2):113432 PMID: 39447411
- 5. Seo HS et al.. 2025. Injinoryeong-San attenuates metabolic dysfunction-associated steatohepatitis via regulation of YAP/TAZ-signaling pathway.. J Ethnopharmacol 353(Pt A):120292 PMID: 40683423
- 6. Sun S et al.. 2021. Neutrophil extracellular traps impair intestinal barrier functions in sepsis by regulating TLR9-mediated endoplasmic reticulum stress pathway.. Cell Death Dis 12(6):606 PMID: 34117211
- 7. Zhao M et al.. 2025. Zhuyu pill attenuates metabolic-associated fatty liver disease by regulating macrophage polarization through TLR4 signaling pathway.. Phytomedicine 138:156439 PMID: 39892308
- 8. Seumen CHT et al.. 2021. Protein phosphatases in TLR signaling.. Cell Commun Signal 19(1):45 PMID: 33882943
